ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC was delisted on the 16th of October, 2018.
42 hedge funds and large institutions have $4.51M invested in ImmunoCellular Therapeutics, Ltd. in 2014 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 2 closing their positions.
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
17% more funds holding
Funds holding: 36 → 42 (+6)
3% less capital invested
Capital invested by funds: $4.67M → $4.51M (-$154K)
13% less call options, than puts
Call options by funds: $121K | Put options by funds: $139K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Callan Capital
La Jolla,
California
|
+$391K |
| 2 |
California Public Employees Retirement System
Sacramento,
California
|
+$252K |
| 3 |
Morgan Stanley
New York
|
+$131K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$60.7K |
| 5 |
Citigroup
New York
|
+$31.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$691K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$35.4K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$12.2K |
| 4 |
U
UBS
Zurich,
Switzerland
|
-$11.7K |
| 5 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$2.75K |
IMUC Hedge Fund Activity: Q2 2014 in Review
42 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics, Ltd. (IMUC) for Q2 2014, worth a combined $4.51M — down 3.3% from $4.67M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new IMUC positions and 2 closed out — a net gain of 6 holders — while 9 added to existing stakes and 6 trimmed.
The largest buyer was Callan Capital, adding an estimated $391K. The largest seller was DAFNA Capital Management, exiting entirely with an estimated $691K sold.
- 42 institutional investors held ImmunoCellular Therapeutics, Ltd. (IMUC) as of Q2 2014, up from 36 in Q1 2014.
- Funds reported $4.51M of ImmunoCellular Therapeutics, Ltd. stock for Q2 2014, down 3.3% quarter-over-quarter.
- 8 funds opened new ImmunoCellular Therapeutics, Ltd. positions in Q2 2014 and 2 closed out, a net change of +6 holders.
- The largest ImmunoCellular Therapeutics, Ltd. buyer in Q2 2014 was Callan Capital, an estimated $391K added.
- The largest ImmunoCellular Therapeutics, Ltd. seller in Q2 2014 was DAFNA Capital Management, an estimated $691K sold.
Based on aggregated 13F filings for Q2 2014.